Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TGFBR2 KO CAR27/IL-15 NK cells · 1 trial · 1 indication
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
| Arm | Type | Description |
|---|---|---|
| Treatment with TROP2 CAR/IL-15 TGFBR2 KO NK cells + Oral Belzutifan | EXPERIMENTAL | Treatment will be administered on an inpatient basis for lymphodepleting therapy, cell infusion and first doses of belzultifan, and on an outpatient basis after patients are dismissed from the hospital and continue self-administering belzultifan at home. |
| Name | Type | Description |
|---|---|---|
| TGFBR2 KO CAR27/IL-15 NK cells | DRUG | Given by mouth |
Inclusion Criteria: 1. Subjects must be 18 years or older. 2. Subjects must be willing and able to provide informed consent. 3. Subjects with a histologically confirmed diagnosis of pancreatic ductal adenocarcinoma or ampullary-type carcinoma 4. Subjects who have progressive disease after receiving...
Top 20 of 68 competitors
TGFBR2 KO CAR27/IL-15 NK cells is an investigational cell therapy being developed for the treatment of pancreatic cancer. It is currently in Phase 1 clinical development, with an active trial recruiting patients in the United States. The therapy is designed for adults aged 18 years and older.
TGFBR2 KO CAR27/IL-15 NK cells is being developed by United Therapeutics Corporation, a biopharmaceutical company listed on the NASDAQ under the ticker symbol UTHR. The company is conducting a Phase 1 clinical trial to evaluate the therapy in patients with pancreatic cancer.
TGFBR2 KO CAR27/IL-15 NK cells is in Phase 1 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. The ongoing Phase 1 trial is currently recruiting participants with pancreatic cancer in the United States.
TGFBR2 KO CAR27/IL-15 NK cells is being evaluated in a Phase 1 clinical trial registered as NCT07377526. The trial, titled 'TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer', is recruiting 37 participants with pancreatic cancer in the United States. The study is uncontrolled and not blinded.
TGFBR2 KO CAR27/IL-15 NK cells is an investigational cell therapy being studied in a clinical trial that also involves TROP2 CAR-engineered cord blood-derived NK cells combined with belzutifan. The trial title references TROP2 CAR NK cells, but the specific therapy TGFBR2 KO CAR27/IL-15 NK cells is distinct in its design.